Proteomics International has granted PHDx, head-quartered in Austin, Texas, a licence for the clinical
market in the USA to make PromarkerD available to the more than 30 million Americans living with
diabetes.
Under the national licence agreement PHDx will develop and commercialise the PromarkerD mass
spectrometry “Laboratory Developed Test” (LDT) in its specialist certified laboratories. The LDT
permits fast adoption of a new test in advanced markets. First sales are anticipated to be in four to six months, and Proteomics International will receive a royalty on all tests sold. Further details of the licence agreement are commercially sensitive and remain confidential.
Kidney disease is responsible for 48,000 deaths a year in the USA—the ninth leading cause of death
PIQ Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)